Small molecules as therapeutic agents for inborn errors of metabolism

[1]  K. Maiese.  Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. , 2016, British journal of clinical pharmacology.

[2]  L. da Cruz,et al.  Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. , 2016, Human molecular genetics.

[3]  J. Poveda,et al.  Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients , 2016, Journal of the Neurological Sciences.

[4]  Zayd M. Khaliq,et al.  A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism , 2016, The Journal of Neuroscience.

[5]  S. Alves,et al.  Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders , 2016, International journal of molecular sciences.

[6]  M. Ferrer,et al.  MCOLN1 is a ROS sensor in lysosomes that regulates autophagy , 2016, Nature Communications.

[7]  S. Haggarty,et al.  Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models , 2016, Molecular and Cellular Neuroscience.

[8]  A. Ballabio,et al.  Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic kidney cells. , 2016, Kidney international.

[9]  J. Ouyang,et al.  A simpler sampling interface of venturi easy ambient sonic-spray ionization mass spectrometry for high-throughput screening enzyme inhibitors. , 2016, Analytica chimica acta.

[10]  L. Meijer,et al.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis , 2016, Journal of Innate Immunity.

[11]  D. Galanaud,et al.  Normalisation of brain spectroscopy findings in Niemann–Pick disease type C patients treated with miglustat , 2016, Journal of Neurology.

[12]  Ying Sun,et al.  CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Yoshiyuki Suzuki,et al.  Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study , 2016, Annals of clinical and translational neurology.

[14]  Melanie V. Leveridge,et al.  The Evolution of MALDI-TOF Mass Spectrometry toward Ultra-High-Throughput Screening: 1536-Well Format and Beyond , 2016, Journal of biomolecular screening.

[15]  E. Ballestar,et al.  Autophagy maintains stemness by preventing senescence , 2016, Nature.

[16]  D. Pearce,et al.  Tissue‐specific variation in nonsense mutant transcript level and drug‐induced read‐through efficiency in the Cln1 R151X mouse model of INCL , 2015, Journal of cellular and molecular medicine.

[17]  P. Taylor,et al.  Panel docking of small-molecule libraries - Prospects to improve efficiency of lead compound discovery. , 2015, Biotechnology advances.

[18]  O. Takikawa,et al.  Affinity imaging mass spectrometry (AIMS): high-throughput screening for specific small molecule interactions with frozen tissue sections. , 2015, The Analyst.

[19]  Yoshiyuki Suzuki,et al.  pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases. , 2015, Angewandte Chemie.

[20]  L. Scott.  Eliglustat: A Review in Gaucher Disease Type 1 , 2015, Drugs.

[21]  R. Morimoto,et al.  The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis. , 2015, Journal of molecular biology.

[22]  D. Ory,et al.  Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1. , 2015, Molecular genetics and metabolism.

[23]  C. Pérez-Cerdá,et al.  The Effects of PMM2‐CDG‐Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein , 2015, Human mutation.

[24]  G. Węgrzyn,et al.  Combined Therapies for Lysosomal Storage Diseases. , 2015, Current molecular medicine.

[25]  A. Di Leonardo,et al.  Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives. , 2015, European journal of medicinal chemistry.

[26]  B. Cormand,et al.  Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases , 2015, PloS one.

[27]  M. Tartaglia,et al.  BCM-95 and (2-hydroxypropyl)-β-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in Sap C-deficient fibroblasts. , 2015, Human molecular genetics.

[28]  Stuart L. Schreiber,et al.  Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics , 2015, Proceedings of the National Academy of Sciences.

[29]  F. Tort,et al.  Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons , 2015, Neurotherapeutics.

[30]  G. Andria,et al.  Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  M. Baba,et al.  Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[32]  M. Balwani,et al.  Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial , 2015, The Lancet.

[33]  Tudor I. Oprea,et al.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes , 2015, Cell.

[34]  K. Higaki,et al.  Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease. , 2015, Biological & pharmaceutical bulletin.

[35]  Mark J Wigglesworth,et al.  Increasing the delivery of next generation therapeutics from high throughput screening libraries. , 2015, Current opinion in chemical biology.

[36]  B. Wang,et al.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease , 2015, Molecular medicine.

[37]  R. Falk,et al.  Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. , 2015, Circulation. Heart failure.

[38]  R. Hopkin,et al.  Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease. , 2015, European journal of medical genetics.

[39]  C. Vite,et al.  Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease , 2015, Science Translational Medicine.

[40]  N. Yui,et al.  β-Cyclodextrin-threaded Biocleavable Polyrotaxanes Ameliorate Impaired Autophagic Flux in Niemann-Pick Type C Disease* , 2015, The Journal of Biological Chemistry.

[41]  H. Hillege,et al.  European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene , 2015, Neuromuscular Disorders.

[42]  R. Giugliani,et al.  Genome Editing: Potential Treatment for Lysosomal Storage Diseases , 2015, Current Stem Cell Reports.

[43]  P. Codogno,et al.  Development of autophagy inducers in clinical medicine. , 2015, The Journal of clinical investigation.

[44]  R. Schiffmann.  The consequences of genetic and pharmacologic reduction in sphingolipid synthesis , 2015, Journal of Inherited Metabolic Disease.

[45]  O. Karayal,et al.  Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis , 2014, Neurology and Therapy.

[46]  C. Charrier,et al.  Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis , 2014, Orphanet Journal of Rare Diseases.

[47]  A. Pichiecchio,et al.  A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  C. Hetz,et al.  Targeting autophagy in neurodegenerative diseases. , 2014, Trends in pharmacological sciences.

[49]  L. Szente,et al.  Cyclodextrins, blood-brain barrier, and treatment of neurological diseases. , 2014, Archives of medical research.

[50]  L. Meijer,et al.  Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del‐CFTR by a CDK‐independent mechanism , 2014, British journal of pharmacology.

[51]  M. Maiuri,et al.  Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation , 2014, Autophagy.

[52]  P. Gascón,et al.  The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann–Pick type C patients carrying missense mutations , 2014, The FEBS journal.

[53]  R. Matsuda,et al.  Discovery of Natural Products Possessing Selective Eukaryotic Readthrough Activity: 3‐epi‐Deoxynegamycin and Its Leucine Adduct , 2014, ChemMedChem.

[54]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[55]  R. Schiffmann,et al.  A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV , 2014, Nature Communications.

[56]  W. Zein,et al.  Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study , 2014, The Lancet Neurology.

[57]  L. Scott.  Tafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy , 2014, Drugs.

[58]  R. Puertollano.  mTOR and lysosome regulation , 2014, F1000prime reports.

[59]  F. Platt,et al.  Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann–Pick disease type C1 mice , 2014, Neurobiology of Disease.

[60]  A. Cuervo,et al.  Autophagy and human disease: emerging themes. , 2014, Current opinion in genetics & development.

[61]  R. Behringer,et al.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. , 2014, Pharmacological research.

[62]  Sougata Ghosh,et al.  Synthesis of 1,5-dideoxy-1,5-iminoribitol C-glycosides through a nitrone-olefin cycloaddition domino strategy: identification of pharmacological chaperones of mutant human lysosomal β-galactosidase. , 2014, The Journal of organic chemistry.

[63]  Andrea Ballabio,et al.  The Phytoestrogen Genistein Modulates Lysosomal Metabolism and Transcription Factor EB (TFEB) Activation* , 2014, The Journal of Biological Chemistry.

[64]  S. Gersting,et al.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators , 2014, Journal of Inherited Metabolic Disease.

[65]  G. Scarano,et al.  Molecular Analysis, Pathogenic Mechanisms, and Readthrough Therapy on a Large Cohort of Kabuki Syndrome Patients , 2014, Human mutation.

[66]  T. Schoeb,et al.  Long-term nonsense suppression therapy moderates MPS I-H disease progression. , 2014, Molecular genetics and metabolism.

[67]  Parisa Lotfi,et al.  2-Hydroxypropyl-β-cyclodextrin Promotes Transcription Factor EB-mediated Activation of Autophagy , 2014, The Journal of Biological Chemistry.

[68]  C. Sheridan.  Doubts raised over 'read-through' Duchenne drug mechanism , 2013, Nature Biotechnology.

[69]  M. Slifker,et al.  Correction of Cystathionine β‐Synthase Deficiency in Mice by Treatment with Proteasome Inhibitors , 2013, Human mutation.

[70]  M. Maiuri,et al.  Towards a rational combination therapy of cystic fibrosis , 2013, Autophagy.

[71]  K. Sandhoff,et al.  Gangliosides and Gangliosidoses: Principles of Molecular and Metabolic Pathogenesis , 2013, The Journal of Neuroscience.

[72]  D. Bichet,et al.  A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. , 2013, Molecular genetics and metabolism.

[73]  Laura Segatori,et al.  Remodeling the Proteostasis Network to Rescue Glucocerebrosidase Variants by Inhibiting ER-Associated Degradation and Enhancing ER Folding , 2013, PloS one.

[74]  Nina Raben,et al.  Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease , 2013, EMBO molecular medicine.

[75]  M. Zeviani,et al.  Phenylbutyrate Therapy for Pyruvate Dehydrogenase Complex Deficiency and Lactic Acidosis , 2013, Science Translational Medicine.

[76]  D. Begley,et al.  Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood–brain barrier permeability , 2013, Journal of Inherited Metabolic Disease.

[77]  M. Horowitz,et al.  Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase , 2013, Blood cells, molecules & diseases.

[78]  R. Giugliani,et al.  Chloramphenicol enhances IDUA activity on fibroblasts from mucopolysaccharidosis I patients. , 2013, Current Pharmaceutical Biotechnology.

[79]  F. Platt,et al.  The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. , 2012, The Journal of cell biology.

[80]  D. Lockhart,et al.  Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies , 2012, Orphanet Journal of Rare Diseases.

[81]  M. Bennett,et al.  Treatment of a methylmalonyl-CoA mutase stopcodon mutation. , 2012, Biochemical and biophysical research communications.

[82]  M. Ugarte,et al.  Readthrough Strategies for Therapeutic Suppression of Nonsense Mutations in Inherited Metabolic Disease , 2012, Molecular Syndromology.

[83]  Rosa Bartolomeo,et al.  Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI , 2012, Journal of Inherited Metabolic Disease.

[84]  D. Rubinsztein,et al.  Autophagy modulation as a potential therapeutic target for diverse diseases , 2012, Nature Reviews Drug Discovery.

[85]  R. Scheule,et al.  Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease , 2012, PloS one.

[86]  M. Ferrer,et al.  Discovery of a novel noniminosugar acid α glucosidase chaperone series. , 2012, Journal of medicinal chemistry.

[87]  Rosemarie E. Venier,et al.  Miglustat as a therapeutic agent: prospects and caveats , 2012, Journal of Medical Genetics.

[88]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[89]  A. Ballabio,et al.  Autophagy in lysosomal storage disorders , 2012, Autophagy.

[90]  J. Rousset,et al.  Statistical Analysis of Readthrough Levels for Nonsense Mutations in Mammalian Cells Reveals a Major Determinant of Response to Gentamicin , 2012, PLoS genetics.

[91]  C. Whitley,et al.  START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. , 2012, Molecular genetics and metabolism.

[92]  S. Sundar,et al.  Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues. , 2012, ACS medicinal chemistry letters.

[93]  G. Węgrzyn,et al.  Genistein in Sanfilippo disease: A randomized controlled crossover trial , 2012, Annals of neurology.

[94]  A. Ballabio,et al.  Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance , 2011, Developmental cell.

[95]  N. Blau,et al.  The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. , 2011, Human Molecular Genetics.

[96]  Laura Segatori,et al.  Lacidipine remodels protein folding and Ca 2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase. , 2011, Chemistry & biology.

[97]  Andrea Ballabio,et al.  TFEB Links Autophagy to Lysosomal Biogenesis , 2011, Science.

[98]  J. Flanagan,et al.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. , 2011, Assay and drug development technologies.

[99]  J. M. Benito,et al.  Pharmacological chaperone therapy for Gaucher disease: a patent review , 2011, Expert opinion on therapeutic patents.

[100]  I. Tanida.  Autophagosome formation and molecular mechanism of autophagy. , 2011, Antioxidants & redox signaling.

[101]  F. Maxfield,et al.  Niemann‐Pick type C disease: molecular mechanisms and potential therapeutic approaches , 2011, Journal of neurochemistry.

[102]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[103]  Laura Segatori,et al.  Ca2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts. , 2011, ACS chemical biology.

[104]  N. Brunetti‐Pierri,et al.  Phenylbutyrate therapy for maple syrup urine disease. , 2011, Human molecular genetics.

[105]  G. Węgrzyn,et al.  Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses , 2011, Metabolic Brain Disease.

[106]  G. A. van der Marel,et al.  Ultrasensitive in situ visualization of active glucocerebrosidase molecules. , 2010, Nature chemical biology.

[107]  S. Sturley,et al.  Niemann–Pick type C pathogenesis and treatment: from statins to sugars , 2010, Clinical lipidology.

[108]  Bart Kus,et al.  Correction of the ΔPhe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine , 2010, Molecular Pharmacology.

[109]  M. Patterson,et al.  Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. , 2010, Molecular genetics and metabolism.

[110]  A. Simeonov,et al.  Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124 , 2010, Proceedings of the National Academy of Sciences.

[111]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[112]  D. Lockhart,et al.  The pharmacological chaperone 1‐deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha‐glucosidase , 2009, Human mutation.

[113]  Yoshiyuki Suzuki,et al.  Chaperone Activity of Bicyclic Nojirimycin Analogues for Gaucher Mutations in Comparison with N‐(n‐nonyl)Deoxynojirimycin , 2009, Chembiochem : a European journal of chemical biology.

[114]  R. Damoiseaux,et al.  Nonaminoglycoside compounds induce readthrough of nonsense mutations , 2009, The Journal of experimental medicine.

[115]  H. Peters,et al.  Stop codon read-through of a methylmalonic aciduria mutation. , 2009, Molecular genetics and metabolism.

[116]  A. Ballabio,et al.  A Gene Network Regulating Lysosomal Biogenesis and Function , 2009, Science.

[117]  Yoshitomo Hamuro,et al.  Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease* , 2009, The Journal of Biological Chemistry.

[118]  J. Gianutsos,et al.  Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment , 2009, Genetics in Medicine.

[119]  T. Butters,et al.  Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease. , 2009, Journal of medicinal chemistry.

[120]  A. Ballabio,et al.  Lysosomal disorders: from storage to cellular damage. , 2009, Biochimica et biophysica acta.

[121]  J. Jakóbkiewicz-Banecka,et al.  Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway , 2009, Journal of Biomedical Science.

[122]  A. Galione,et al.  Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium , 2008, Nature Medicine.

[123]  John R. Yates,et al.  Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases , 2008, Cell.

[124]  John J. Mitchell,et al.  A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. , 2008, Molecular genetics and metabolism.

[125]  Eitan Kerem,et al.  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial , 2008, The Lancet.

[126]  B. Moore,et al.  Advances in and applications of proteasome inhibitors. , 2008, Current opinion in chemical biology.

[127]  J. Haavik,et al.  Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase , 2008, Journal of neurochemistry.

[128]  E. White,et al.  Adapting Cell-Based Assays to the High-Throughput Screening Platform: Problems Encountered and Lessons Learned , 2008, JALA.

[129]  S. Peltz,et al.  PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model , 2008, Proceedings of the National Academy of Sciences.

[130]  J. Rousset,et al.  Drug‐induced readthrough of premature stop codons leads to the stabilization of laminin α2 chain mRNA in CMD myotubes , 2008, The journal of gene medicine.

[131]  K. Michals‐Matalon,et al.  Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria , 2008, Expert opinion on investigational drugs.

[132]  F. Ruschitzka,et al.  Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia , 2007, Heart.

[133]  D. Kass,et al.  Therapeutic Potential of Tetrahydrobiopterin for Treating Vascular and Cardiac Disease , 2007, Journal of cardiovascular pharmacology.

[134]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[135]  J. Shayman,et al.  A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. , 2007, Molecular genetics and metabolism.

[136]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[137]  T. Stockley,et al.  Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 Gangliosidosis* , 2007, Journal of Biological Chemistry.

[138]  A. Ballabio,et al.  Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[139]  J. Fletcher,et al.  Inhibition of Glycosaminoglycan Synthesis Using Rhodamine B in a Mouse Model of Mucopolysaccharidosis Type IIIA , 2006, Pediatric Research.

[140]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[141]  D. Brooks,et al.  Stop-codon read-through for patients affected by a lysosomal storage disorder. , 2006, Trends in molecular medicine.

[142]  L. Maquat,et al.  Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. , 2006, Trends in molecular medicine.

[143]  M. Kaiser-Kupfer,et al.  Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. , 2006, Ophthalmology.

[144]  ウィーバー，ドナルド，エフ．,et al.  Treatment of protein folding disorders , 2006 .

[145]  G. Węgrzyn,et al.  Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses , 2006, European Journal of Human Genetics.

[146]  D. Bedwell,et al.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model , 2006, Journal of Molecular Medicine.

[147]  C. Ainsworth.  Nonsense mutations: Running the red light , 2005, Nature.

[148]  J. Sancho,et al.  Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. , 2005, Blood cells, molecules & diseases.

[149]  François Stricher,et al.  The FoldX web server: an online force field , 2005, Nucleic Acids Res..

[150]  R. Gatti,et al.  Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[151]  R. Stevens,et al.  Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations , 2004, Human mutation.

[152]  Å. Sjöholm,et al.  Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[153]  R. Dwek,et al.  Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C , 2004, Neurobiology of Disease.

[154]  R. Desnick,et al.  Enzyme replacement and enhancement therapies for lysosomal diseases , 2004, Journal of Inherited Metabolic Disease.

[155]  D. Sillence,et al.  alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. , 2004, Journal of molecular biology.

[156]  K. Du,et al.  Curcumin, a Major Constituent of Turmeric, Corrects Cystic Fibrosis Defects , 2004, Science.

[157]  J. Rousset,et al.  Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment , 2004, Gene Therapy.

[158]  Uwe Fass,et al.  Readthrough of dystrophin stop codon mutations induced by aminoglycosides , 2004, Annals of neurology.

[159]  J. Lykke-Andersen,et al.  New insights into the formation of active nonsense-mediated decay complexes. , 2003, Trends in biochemical sciences.

[160]  L. Køber,et al.  Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. , 2003, American journal of physiology. Heart and circulatory physiology.

[161]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[162]  S. Hofmann,et al.  The effects of lysosomotropic agents on normal and INCL cells provide further evidence for the lysosomal nature of palmitoyl-protein thioesterase function. , 2002, Biochimica et biophysica acta.

[163]  John Geibel,et al.  Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells , 2002, Nature Medicine.

[164]  J. Mendell,et al.  When the Message Goes Awry Disease-Producing Mutations that Influence mRNA Content and Performance , 2001, Cell.

[165]  D. Marsden,et al.  Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. , 2001, Clinical chemistry.

[166]  J. Clancy,et al.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.

[167]  Jean-Pierre Rousset,et al.  UAG readthrough in mammalian cells: Effect of upstream and downstream stop codon contexts reveal different signals , 2001, BMC Molecular Biology.

[168]  J. Thompson,et al.  Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. , 2001, Human molecular genetics.

[169]  D. Bedwell,et al.  Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. , 2000, RNA.

[170]  A. Avital,et al.  A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. , 2000, American journal of respiratory and critical care medicine.

[171]  F. Cañada,et al.  Generalized anomeric effect in action: synthesis and evaluation of stable reducing indolizidine glycomimetics as glycosidase inhibitors. , 2000, The Journal of organic chemistry.

[172]  H. Sweeney,et al.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. , 1999, The Journal of clinical investigation.

[173]  V. Perry,et al.  Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[174]  P. Tulkens,et al.  Aminoglycosides: Nephrotoxicity , 1999, Antimicrobial Agents and Chemotherapy.

[175]  P. Tulkens,et al.  Aminoglycosides: Activity and Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[176]  J. Clancy,et al.  Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line , 1997, Nature Medicine.

[177]  V. Perry,et al.  Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. , 1997, Science.

[178]  D. Bedwell,et al.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations , 1996, Nature Medicine.

[179]  A. Meijer,et al.  Phosphorylation of Ribosomal Protein S6 Is Inhibitory for Autophagy in Isolated Rat Hepatocytes (*) , 1995, The Journal of Biological Chemistry.

[180]  G. Cortopassi,et al.  Proposed molecular and cellular mechanism for aminoglycoside ototoxicity , 1994, Antimicrobial Agents and Chemotherapy.

[181]  Lysosomal Storage Diseases , 1986, The Lancet.

[182]  B. D. Davis,et al.  Triphasic concentration effects of gentamicin on activity and misreading in protein synthesis. , 1979, Biochemistry.

[183]  Shagun Krishna,et al.  Virtual screening strategies: recent advances in the identification and design of anti-cancer agents. , 2015, Methods.

[184]  K. Lyseng-Williamson.  Miglustat: A Review of Its Use in Niemann-Pick Disease Type C , 2013, Drugs.

[185]  D. Bedwell,et al.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. , 2012, Molecular genetics and metabolism.

[186]  J. Clarke,et al.  An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). , 2011, Molecular genetics and metabolism.

[187]  T. Ueno,et al.  LC3 and Autophagy. , 2008, Methods in molecular biology.

[188]  A. Reuser,et al.  Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. , 2007, Molecular genetics and metabolism.

[189]  A. Ballabio,et al.  Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[190]  D. Chace,et al.  The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. , 2002, Annual review of genomics and human genetics.

[191]  D. Sleat,et al.  Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.